Overall, 226 patients were included. A total of 457 stents were evaluated (2.0 ± 1.4 per patient). Mean stent diameter was 2.9 ± 0.45 mm. In 61%, a high-pitch protocol was employed. Mean dose-length product (DLP) of CCTA was 159.2 mGy cm, corresponding to 2.2 mSv using a conversion factor of k = 0.014. Mean amount of contrast agent was 58.3 ± 12.5 ml. In 145 patients (64%), CCTA was negative. In this group, one MACE occurred (acute coronary syndrome) during follow-up in a patient who had also undergone unremarkable ICA. In 23 patients (10%), CCTA detected 28 ISR which were confirmed and treated by ICA (true positive). In 27 patients (12%), ISR was suspected by CCTA but excluded by ICA (false positive), 30 patients (13%) had unclear findings and normal non-invasive tests. No MACE occurred during follow-up in these patients. One patient was misclassified in CCTA as having intermediate and not high-grade ISR who underwent revascularization within 3 months. Eleven patients (5%) were lost to follow-up. During follow-up, eight patients had myocardial infarctions due to five ISRs and three de novo lesions. No patient died. In cases with unclear or false-positive findings, the amount of stents was significantly higher, stents were smaller and patients had a higher BMI.